Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: Real-life experience in Finnish patients

Scandinavian Journal of Rheumatology

Volumn 38, Issue 5, 2009, Pages 323-327

  Valleala, H ^a   Korpela, M ^b   Mottonen T ^c   Hienonen Kempas, T ^d   Kauppi, M ^e   Hannonen, P ^f   Leirisalo Repo, M ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

^d Heinola ^*

^e RHEUMATISM FOUNDATION HOSPITAL   (Finland)

^f JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; AURANOFIN; AUROTHIOMALATE; AZATHIOPRINE; CHLORAMBUCIL; CYCLOSPORIN; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; PODOPHYLLOTOXIN; PREDNISOLONE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGED; ARTICLE; BACTERIAL ARTHRITIS; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCARDITIS; ERYSIPELAS; FEMALE; FINLAND; FOLLOW UP; HUMAN; LISTERIOSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYCOPLASMA PNEUMONIA; OSTEOMYELITIS; PNEUMONIA; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHI-SQUARE DISTRIBUTION; DRUG THERAPY, COMBINATION; FEMALE; FINLAND; HUMANS; MALE; MEDICAL RECORDS; METHOTREXATE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; PREDNISOLONE; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 70350068583     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740902946355     Document Type: Article

References (12)

1. Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999;/353:/ 1568-73.
2. Voll RE, Kalden JR. Do we need new treatment that goes beyond tumor necrosis factor blockers for rheumatoid arthritis? Ann N Y Acad Sci 2005;/1051:/799-810.
3. Emery P. Rituximab in rheumatoid arthritis: a viewpoint by Paul Emery. Bio Drugs 2007;/21:/342.
4. Edwards JC, Szczepanski L, Szechinski J, Filipowicz- Sosnowska A, Emery P, Close DR, et al. Efficacy of B-celltargeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;/350:/2572-81. (Pubitemid 38758544)
5. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;/54:/1390-400.
6. Cohen SB, Emery P, GreenwaldMW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebocontrolled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;/54:/ 2793-806.
7. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;/31:/315-24.
8. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, den de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;/38:/44-8.
9. van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organisation/International League Against Rheumatism criteria. Arthritis Rheum 1996;/39:/34-40.
10. Assous N, Gossec L, Dieudé P, Meyer O, Dougados M, Kahan A, et al. Rituximab therapy in rheumatoid arthritis in daily practice. J Rheumatol 2008;/35:/31-4.
11. Jois RN, Masding A, Somerville M, Gaffney K, Scott DG. Rituximab therapy in patients with resistant rheumatoid arthritis: real-life experience. Rheumatology (Oxford) 2007;/46:/ 980-2.
12. Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007;/56:/3896-908.